Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE DDC Medical (DDC)
FAIRFIELD, Ohio, Feb. 25, 2014 /PRNewswire/ -- DDC Medical (DDC), one of the world's largest DNA testing laboratories, announced today the signing of a license agreement with the National Institute of Standards and Technology (NIST) to commercialize mouse cell line authentication (M-CLA) using STR DNA technology. According to Hughes P. Marshall D, Reid Y, et al. 2007 BioTechniques 43.575-586, it has been shown that over a third of cell lines used for biomedical research are contaminated or misidentified resulting in wasted resources, unreliable data, and irreproducible results.
Mouse cell lines are commonly used as model systems to study human diseases. According to Dr. Michael Baird, the Chief Science Officer at DDC, "The addition of mouse cell line authentication is a major step in maintaining the efficacy of biomedical research using cell lines. We are honored to work with NIST to bring this vitally important test to market."
The DDC Medical mouse cell line authentication test uses STR DNA analysis to characterize the mouse DNA. The loci selected produce stable, robust results based on a tetranucleotide repeat, similar to the types of loci examined for human cell line authentication (H-CLA). Other mouse cell line tests available use either dinucleotide repeat STR loci that are difficult to interpret, or large SNP arrays that are expensive and time consuming to perform. The DDC Medical mouse cell line authentication test is inexpensive with a short turnaround time.
DDC Medical currently provides human cell line authentication and mycoplasma detection to academic researchers, biotech, and bio pharma customers. Recent emphasis by scientific Journals to authenticate cell lines prior to publication has increased awareness of the issues of cell line contamination and misidentification. Funding sources are also strongly recommending that appropriate quality controls be implemented to ensure cell line integrity. In late 2013, the Prostate Cancer Foundation initiated requirements to authenticate cell lines used by the PCF's grant recipients.
DDC's CEO, Peter Vitulli stated, "With Dr. Baird's direction, DDC Medical is honored to collaborate with NIST to address contaminated and misidentified mouse cell lines."
About Dr. Baird:
Dr. Michael L. Baird, Chief Science Officer of DDC Medical, is considered one of the foremost experts in DNA and paternity testing. He is the first person to testify in a criminal DNA case in the US, and has testified in over 350 court cases involving DNA evidence. He is currently a member of the Relationship Testing Standards Committee of the AABB responsible for developing standards for paternity testing. Dr. Baird has authored or coauthored over 50 peer reviewed scientific articles involving DNA identification analysis. He has served as an on-air consultant to NBC, CNN, MSNBC, Fox News and many of the world's leading news outlets. Dr. Baird received his PhD in Genetics from the University of Chicago and was a postdoctoral fellow at the University of Michigan in the department of human genetics and a Research Associate at Columbia University in the departments of human genetics and medicine. Dr. Baird served on the panel of the Office of Technology Assessment for the U.S. Congress studying the use of DNA for identification. He also presented information to the panels of the National Research Council that studied DNA testing methods and issued reports.
About DDC Medical (DDC):
DDC Medical, a division of DDC, is one of the world's largest DNA testing companies. Founded 19 years ago, DDC offers comprehensive DNA testing services for paternity and other family relationships, forensics, cell line authentication, and ancestry. DDC receives more than 800,000 consumer calls each year and performs over half a million tests annually. The company is known for its groundbreaking technologies, including an exclusive license for the most innovative and accurate non-invasive prenatal paternity test using next generation sequencing (NGS) technology, which only requires a simple blood draw from the mother and alleged father. DDC's unique Dual Process™ ensures all professionally collected DNA samples are independently tested twice producing legal results of unmatched quality and reliability. DDC is accredited by 7 national and international organizations. For more information: http://www.ddcmedical.com or 1-888-362-3928.
©2012 PR Newswire. All Rights Reserved.